These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

256 related items for PubMed ID: 32000551

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study).
    Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S, Nomura A, Yoshida S, Nishimoto N.
    Ann Rheum Dis; 2018 Mar; 77(3):348-354. PubMed ID: 29191819
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of biological agents in the treatment of patients with Takayasu arteritis: a systematic review and meta-analysis.
    Shuai ZQ, Zhang CX, Shuai ZW, Ge SL.
    Eur Rev Med Pharmacol Sci; 2021 Jan; 25(1):250-262. PubMed ID: 33506914
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Pathophysiology of large vessel vasculitis and utility of interleukin-6 inhibition therapy.
    Yoshifuji H.
    Mod Rheumatol; 2019 Mar; 29(2):287-293. PubMed ID: 30427262
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treatment efficacy and safety of adalimumab versus tocilizumab in patients with active and severe Takayasu arteritis: an open-label study.
    Wang J, Kong X, Ma L, Ding Z, Chen H, Chen R, Jin X, Chen C, Lin J, Jiang L.
    Rheumatology (Oxford); 2024 May 02; 63(5):1359-1367. PubMed ID: 37540159
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Systematic review and meta-analysis of the current literature on tocilizumab in patients with refractory Takayasu arteritis.
    Kang L, Liu Y, Luo Z, Zhou Y, Chen B, Yin G, Xie Q.
    Front Immunol; 2023 May 02; 14():1084558. PubMed ID: 36845158
    [Abstract] [Full Text] [Related]

  • 13. Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study.
    Nakaoka Y, Isobe M, Tanaka Y, Ishii T, Ooka S, Niiro H, Tamura N, Banno S, Yoshifuji H, Sakata Y, Kawakami A, Atsumi T, Furuta S, Kohsaka H, Suzuki K, Hara R, Maejima Y, Tsukamoto H, Takasaki Y, Yamashita K, Okada N, Yamakido S, Takei S, Yokota S, Nishimoto N.
    Rheumatology (Oxford); 2020 Sep 01; 59(9):2427-2434. PubMed ID: 31951279
    [Abstract] [Full Text] [Related]

  • 14. Tocilizumab treatment in childhood Takayasu arteritis: Case series of four patients and systematic review of the literature.
    Batu ED, Sönmez HE, Hazırolan T, Özaltın F, Bilginer Y, Özen S.
    Semin Arthritis Rheum; 2017 Feb 01; 46(4):529-535. PubMed ID: 27515155
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The efficacy of tocilizumab for the treatment of Chinese Takayasu's arteritis.
    Zhou J, Chen Z, Li J, Yang Y, Zhao J, Chen H, Liu M, Sun F, Li M, Tian X, Zeng X.
    Clin Exp Rheumatol; 2017 Feb 01; 35 Suppl 103(1):171-175. PubMed ID: 28406764
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Biological treatments in giant cell arteritis & Takayasu arteritis.
    Samson M, Espígol-Frigolé G, Terrades-García N, Prieto-González S, Corbera-Bellalta M, Alba-Rovira R, Hernández-Rodríguez J, Audia S, Bonnotte B, Cid MC.
    Eur J Intern Med; 2018 Apr 01; 50():12-19. PubMed ID: 29146018
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.